- Pure Extracts Technologies Corp.’s subsidiary Pure Mushrooms Corp. has submitted an application to Health Canada for a Dealer’s License
- Award of a Dealer’s License will enable company to procure controlled substances, conduct research, carry out business-to-business sales
- Pure Extracts has recently commenced a study into psilocybin-based active treatments, with research set to be carried out under auspices of Toronto Institute of Pharmaceutical Technology
- Functional mushroom, psychedelic drug market is forecast to grow to value of $6.85 billion by 2027
Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, announced that its wholly owned subsidiary, Pure Mushrooms Corp., had submitted an application to Health Canada for a Dealer’s License under the Controlled Drugs and Substances Act (“CDSA”) (https://ibn.fm/W0X2t).
Under the CDSA’s regulations, companies are required to obtain a license issued by Health Canada to carry out a variety of regulated activities with controlled substances. Among other items, the award of a license would effectively enable Pure Mushrooms Corp. to…
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.